Table 5.
Percentages of MBP-stimulated cytokine producing blood cells from patients with different MS phenotypes.
| Cell type | BMS | RRMS | SPMS | BMS versus RRMS | BMS versus SPMS | SPMS versus RRMS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LS mean | 95% CL | LS mean | 95% CL | LS mean | 95% CL | |||||||
| CD4+IL17+ | 0.07 | −0.02 | 0.21 | 0.09 | −0.07 | 0.24 | 0.12 | 0.02 | 0.23 | ns | ns | ns |
| CD4+IFNγ+ | 0.02 | −0.14 | 0.17 | 0.16 | −0.09 | 0.42 | 0.13 | −0.08 | 0.34 | ns | ns | ns |
| CD14+IL12p35+ | 2.02 | 0.90 | 3.13 | 0.93 | −0.80 | 2.65 | 1.17 | −0.08 | 2.42 | ns | ns | ns |
| CD14+IL6+ | 15.24 | 10.53 | 19.96 | 1.72 | −4.82 | 8.27 | 0.64 | −4.03 | 5.32 | 0.004 | <0.0001 | ns |
| CD4+IL13+ | 0.16 | 0.13 | 0.20 | 0.12 | 0.06 | 0.17 | 0.11 | 0.07 | 0.15 | ns | ns | ns |
| CD4+IL25+ | 0.48 | 0.40 | 0.56 | 0.60 | 0.48 | 0.72 | 0.18 | 0.08 | 0.27 | ns | <0.0001 | <0.0001 |
| CD14+IL10+ | 13.14 | 4.78 | 21.50 | 11.80 | −0.05 | 23.64 | 20.32 | 11.32 | 29.32 | ns | ns | ns |
| CD14+TGFβ+ | 2.02 | −0.63 | 4.66 | 5.52 | 1.66 | 9.38 | 4.83 | 2.03 | 7.62 | ns | ns | ns |
| CD4+BDNF+ | 1.77 | −2.31 | 5.84 | 9.76 | 2.81 | 16.71 | 0.61 | −3.68 | 4.90 | ns | ns | ns |
Data are reported as least squares (LS) means and 95% confidence limits. Between-group comparison P values were corrected with Tukey-Kramer and the following variables were taken as covariates: therapy (dichotomic variable: yes/no), age, and gender; ns: not significant.